Pfizer in South Africa was established in 1953. Since then the company has been shaped by developments within the global Pfizer group, including the acquisition of Warner Lambert, Pharmacia and most recently, Wyeth.
Brian Daniel, CEO & Country Manager for Pfizer South Africa’s Biopharmaceutical Division, notes that the recent acquisition of Wyeth has proved particularly positive for the company, having broadened the spectrum of diseases that Pfizer is able to address. ‘Our offering now spans medication for pain, women’s health, cardio-vascular health, neuroscience and vaccines’, he enthuses.
The addition of a vaccine offering is of particular importance because it is in line with government’s aims to address infant mortality.
Products and services
Several of Pfizer’s medicine are world leaders in their therapeutic class.
Four of the company’s top ten products are world-leading pharmaceuticals discovered by scientists at the Pfizer discovery and development campus. These include medicines for treating high blood pressure and angina, the worlds best selling oral anti-fungal agent, a treatment for benign prostatic hypertrophy, and the first oral treatment for erectile dysfunction.
Research has concentrated recently on:
Diseases of the central nervous system
Inflammatory diseases (rheumatoid arthritis and osteo-arthritis)
Viral diseases (HIV/AIDS)
Allergies and respiratory diseases
Research is also undertaken to improve the health of both farm livestock and family pets.
Pfizer prescription-only medicines include anti-infectives treatments for cardiovascular diseases, depression and erectile dysfunction anti inflammatories, anti-epileptics and many others.
Address:85 Bute Rd, Sandown, Sandton, 2196, South Africa
Tel: 0860 734 937